Øystein Tveiten

MD, PhD, (radio)neurosurgeon, hobby neurologist, part time marathoner, wannabe photographer in full time midlife crisis.

[Øystein Tveiten @mcmio]

@C_Askenberg Nintendo DS

[Matthew L. Carlson, MD MBA @MattCarlsonMD]

Important clinical considerations surrounding bone conduction implant use in patients with chronic otitis or #vestibularschwannoma. Great job @AshleyNassiri! @MayoRadiology @MayoClinicENT @MayoClinicNeuro

https://t.co/wLm7RwFRjN

[Gustavo @gusviani]

🎙 preoperative SRS has a favorable risk-benefit profile and deserves a pH3 trial❗️@OncoAlert @JAMAOnc
📌Multi🏥cohort
- 👥w/ BMs treated between 2005-2021
- Pre🔪SRS: Median dose 15 Gy or 24 Gy, delivered 2 days pre🔪
🥇🎯: LR, meningeal diissemination (MD), radionecrosis &OS
📊RESULTs
- 404 👥/416 lesions 🔪
- 2-ycavity LR: 13.7% (Factors🔄Systemic status, resection extent, surgery type, tumor type)
- 2-y MD: 5.8% (Factors🔄Resection extent, tumor type)
- 2-y ARE: 7.4% (Factors🔄Margin expansion, melanoma)
- Median OS: 17.2 m
#radonc #surgey #neurooncology

[Øystein Tveiten @mcmio]

@JonathanVermaMD @AshwinShindeMD @BhishamCheraMD They are the same. We are working on a longer FU. Perhaps there are differences in the long term.

[Øystein Tveiten @mcmio]

@ParikhSimul @BhishamCheraMD No clinical benefit. Only a volumetric / tumor control benefit. Wait and watch is safe in small- and medium sized VS.

[Øystein Tveiten @mcmio]

@sunjay_shah @BhishamCheraMD That is the point exactly. The wait and watch alternative is safe.

[Mayfield Brain & Spine @MayfieldClinic]

Acoustic neuromas, also called vestibular schwannoma, are benign, slow-growing tumors that can affect hearing and balance. We join @ANAssociation to help sponsor #ANAwarenessWeek2023. Learn more about #acousticneuroma in our Health Topics Library at https://t.co/Y7fCSPtIUK.

[Øystein Tveiten @mcmio]

@northwoods1980 Trumpeted IAM sign. Nicely spotted.

[Øystein Tveiten @mcmio]

@SahgalArjun @gusviani @OncoAlert @JAMA_current Thank you.

[Matthew L. Carlson, MD MBA @MattCarlsonMD]

HOT OFF THE PRESS! New disease specific quality of life instrument for #vestibularschwannoma #acousticneuroma @MayoClinicENT @MayoClinicNeuro @ANAssociation

https://t.co/rHPgx8DGEl

[Øystein Tveiten @mcmio]

@drjonathanchung You are right. There is a volumetric benefit, but with these small / earliest stage tumors - there was no clinical benefit in the 4 year perspective. I think the results justify the conservative approach with postponed treatment until proven growth.

[Øystein Tveiten @mcmio]

@singhv2003 We don’t have any difficulties with lost to follow-up in our country. The patients adhere. But this can be different elsewhere, like in the US: https://t.co/9dUSQAkSVt

[Øystein Tveiten @mcmio]

@aswinchari @PatrickGrover4 @drtintin99 If lost to follow-up is an issue, there is a benefit. The tumor will likely not grow. If patient is adherent to the MRI controls, it is clinically safe to wait for growth. More long term follow up is needed for the most controversial topic (hearing). We are working on that.

[Øystein Tveiten @mcmio]

@drjonathanchung We were not looking for a «good» result. We compared two common treatment strategies.

[Øystein Tveiten @mcmio]

@RaulMatute19 @acampsmalea @OncoAlert Which was important to demonstrate.

[Alizée Camps - - Maléa @acampsmalea]

📍The V-REX randomized clinical trial

➡️ small & medium-sized vestibular schwannoma
➡️diagnosed < 6 months
➡️ 100 patients

👉at 4 years : ✨upfront radiosurgery✨more effective at reducing tumor volume than wait & scan approach

@OncoAlert #OncoAlertAF

https://t.co/iMWESzx5gb

[George Bovis @drbovis]

“Among patients with newly diagnosed small- and medium-sized vestibular schwannoma, upfront radiosurgery demonstrated a significantly greater tumor volume reduction at 4 years than a wait-and-scan approach with treatment upon tumor growth”-JAMA #gammaknife https://t.co/2rz70vS56d

[JAMA @JAMA_current]

Among patients with small or medium vestibular schwannoma, a treatment strategy consisting of upfront radiosurgery was more effective at reducing tumor volume at 4 years than was the initial wait-and-scan approach. https://t.co/Qv3YZVsq2Q

[Øystein Tveiten @mcmio]

@PDBrownOnc Thanks!